Patents Assigned to Phibro Animal Health Corporation
  • Publication number: 20220184198
    Abstract: Inactivated antigens have only been used in avian medicine in parenterally administered vaccines. The only mucosally administered vaccines have been live, modified live, or attenuated vaccines. However, live vaccines have several disadvantages, including the risk of causing disease. Disclosed embodiments concern a composition comprising inactivated bacterial and/or viral antigens that is formulated for mucosal administration to an avian, and a method of using the composition. In certain embodiments, the composition comprises inactivated Clostridium perfringens type A antigens, and/or Salmonella spp. antigens, such as antigens from Salmonella kentucky, Salmonella typhimurium, and/or Salmonella enteriditis, or E. coli antigens. The composition may comprise a polyacrylic acid adjuvant. The composition may be administered to an avian in ovo, during the first 14 days after hatching, or after the first 14 days.
    Type: Application
    Filed: January 24, 2022
    Publication date: June 16, 2022
    Applicant: Phibro Animal Health Corporation
    Inventors: Peter Winter, Karen Brown, Michelle Mathiesen, Hailong Guo, Jeremy Griffel, Sam Christenberry, Meghan Quinn, Hector Cervantes, Bereket Zekarias
  • Publication number: 20220105170
    Abstract: Peptides predicted to be immunogenic against African swine fever virus (ASFV) and vaccine compositions that include the peptides are disclosed herein. In some embodiments, these compositions comprise or consist of one or more peptides comprising the amino acid sequence set forth in SEQ ID NOs: 2-2273. In other embodiments, the compositions comprise viral vectors or host cells, or combinations thereof, that comprise one or more of the peptides. In other embodiments, the compositions comprise nucleic acid molecules comprising one or more of the peptides. The compositions disclosed can include one or more additional components, such as, but not limited to, a carrier, an adjuvant, an additional therapeutic, or combinations thereof. Containers and kits that comprise the compositions are described. Uses of the compositions can include administration to an animal to induce an immune response in the animal, or to immunize the animal against ASFV.
    Type: Application
    Filed: December 17, 2021
    Publication date: April 7, 2022
    Applicants: Phibro Animal Health Corporation, Life Science Research Israel Ltd.
    Inventors: Avner Finger, Avi Zrachya, Ofer Cohen, Anat Zvi
  • Publication number: 20210229139
    Abstract: Pulse dosing is used to administer a cleaning formulation into a fluid process stream flowing through structural components of a processing facility. The fluid process stream may contain corn, corn-derived products, or a combination thereof, or the fluid process stream may contain a process condensate, a rinse fluid, a cleaning fluid or any combination thereof. The processing facility may be an ethanol processing plant, a protein processing plant, a corn oil processing plant, an ethanol and corn oil processing plant, an ethanol and protein processing plant, or an ethanol, corn oil and protein processing plant. Pulse dosing may include administering the cleaning formulation into the fluid process stream for a period of x seconds every y minutes, with no administration of the cleaning formulation between the periods of x seconds.
    Type: Application
    Filed: January 26, 2021
    Publication date: July 29, 2021
    Applicant: Phibro Animal Health Corporation
    Inventor: David Fowlie
  • Patent number: 11000585
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: May 11, 2021
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20210113647
    Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.
    Type: Application
    Filed: December 23, 2020
    Publication date: April 22, 2021
    Applicants: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
  • Patent number: 10918711
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: April 17, 2019
    Date of Patent: February 16, 2021
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Patent number: 10912810
    Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.
    Type: Grant
    Filed: July 29, 2019
    Date of Patent: February 9, 2021
    Assignees: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
  • Publication number: 20200296972
    Abstract: A composition useful for application to plants, seeds or soil to inhibit fungal infections comprising a protein source inoculated with from 5×107 cfu to 5×109 cfu of a Bacillus amyloliquefaciens strain per gram of the protein source.
    Type: Application
    Filed: April 13, 2020
    Publication date: September 24, 2020
    Applicant: Phibro Animal Health Corporation
    Inventors: Christopher J. Reuter, Steven J. MacKenzie
  • Patent number: 10716310
    Abstract: A process for inhibiting foodborne pathogens and reducing foodborne disease involves contacting a living animal, a dressed carcass, or a cut of meat with an effective amount of a bacillus strain exhibiting antibacterial activity. Strains of antibacterial bacillus that are particularly effective for inhibiting Vibrio were discovered. These include Bacillus licheniformis OBT 712 and Bacillus amyloliquefaciens OBT 618.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 21, 2020
    Assignee: Phibro Animal Health Corporation
    Inventors: Christopher J. Reuter, Steven J. MacKenzie, Lauren G. Danielson, Vincent Scuilla
  • Publication number: 20200178548
    Abstract: A process for inhibiting foodborne pathogens and reducing foodborne disease involves contacting a living animal, a dressed carcass, or a cut of meat with an effective amount of a bacillus strain exhibiting antibacterial activity. Strains of antibacterial bacillus that are particularly effective for inhibiting Vibrio were discovered. These include Bacillus licheniformis OBT 618 and Bacillus amyloliquefaciens OBT 712.
    Type: Application
    Filed: February 21, 2020
    Publication date: June 11, 2020
    Applicant: Phibro Animal Health Corporation
    Inventors: Christopher J. Reuter, Steven J. MacKenzie, Lauren G. Danielson, Vincent Scuilla
  • Patent number: 10660930
    Abstract: The present disclosure concerns embodiments of a combination and/or composition comprising bacillus, and yucca, quillaja or both. Embodiments of methods of making and using the combination and/or composition also are disclosed herein. In some embodiments, the combination and/or composition may be used to improve feed conversion rates in animals. In some embodiments the animals are avians; in other embodiments, the animals are non-avians. Embodiments of the disclosed combination can comprise a first composition comprising Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans. Embodiments of the disclosed composition can comprise Quillaja saponaria, Yucca schidigera, or both, and Bacillus coagulans.
    Type: Grant
    Filed: May 11, 2018
    Date of Patent: May 26, 2020
    Assignees: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: David Calabotta, Wendell Knehans, Derek McLean
  • Patent number: 10653151
    Abstract: A composition useful for application to plants, seeds or soil to inhibit fungal infections comprises a protein source inoculated with from 5×107 cfu to 5×109 cfu of a Bacillus amyloliquefaciens strain per gram of the protein source.
    Type: Grant
    Filed: February 1, 2018
    Date of Patent: May 19, 2020
    Assignee: Phibro Animal Health Corporation
    Inventors: Christopher J. Reuter, Steven J. MacKenzie
  • Publication number: 20200054631
    Abstract: Disclosed compositions comprise a therapeutic agent and a carrier selected, or processed to have, an acceptable composite flow index, a granular particle size of 18 mesh to 80 mesh, or both, such as processed granular wheat middlings. The composition may also comprise an oil and/or micro tracers. Suitable granular wheat middlings may have a size range of from 18 mesh to 80 mesh, such as 20 mesh to 80 mesh. The composition has improved flowability characteristics, compared to a composition where the carrier, such as processed wheat middlings, are powdered and/or flakey. Certain embodiments concern a composition comprising, consisting essentially of, or consisting of, nicarbazin, granular wheat middlings, soybean oil and micro tracers. The composition may be administered to an animal, for example, to treat or prevent coccidiosis. Also disclosed herein are methods for making and using the composition.
    Type: Application
    Filed: October 28, 2019
    Publication date: February 20, 2020
    Applicant: Phibro Animal Health Corporation
    Inventors: Ian John Wilkinson, Charles Hollett Fahrenholz
  • Publication number: 20190350998
    Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.
    Type: Application
    Filed: July 29, 2019
    Publication date: November 21, 2019
    Applicants: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
  • Patent number: 10413581
    Abstract: Disclosed herein are embodiments of a combination and/or composition for administration to animals. In some embodiments, the combination and/or composition can be administered to treat and/or prevent a disease in animals. In some embodiments, the combination and/or composition can be administered to promote animal health. In some embodiments, the combination comprises a composition comprising Yucca schidigera, Quillaja saponaria, and combinations thereof and a composition comprising an antimicrobial, an antibiotic, an anticoccidial, a vaccine, or combinations thereof. The combinations or compositions disclosed herein can also improve feed conversion rates in animals.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 17, 2019
    Assignees: Phibro Animal Health Corporation, Desert King International LLC
    Inventors: Kenneth W. Bafundo, A. Bruce Johnson, David Calabotta, Wendell Knehans
  • Publication number: 20190247490
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Application
    Filed: April 17, 2019
    Publication date: August 15, 2019
    Applicant: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20190231864
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Application
    Filed: March 14, 2019
    Publication date: August 1, 2019
    Applicant: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Publication number: 20190202868
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Application
    Filed: March 15, 2019
    Publication date: July 4, 2019
    Applicant: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim
  • Patent number: 10279031
    Abstract: The majority of the mortality observed in young pigs occurs between three and five weeks post-weaning for S. suis infections and between four and six weeks post-weaning for H. parasuis and Actinobacillus suis infections. Clinical disease control associated with S. suis, A. suis and H. parasuis has been attempted using antibiotic treatment, by controlled exposure with live organisms, and by vaccination, using either inactivated commercial or autogenous bacterins administered parenterally. A similar lack of protection in very young pigs is observed with various viruses including swine influenza virus, porcine reproductive and respiratory syndrome virus, porcine epidemic diarrhea virus and rotavirus. Disclosed herein is an immunogenic composition comprising inactivated antigens and a mucosal adjuvant.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventors: Grant Weaver, Jeffrey Alan Kula, Boh Chang Lin, Karen Brown, Wesley W. Johnson, Michael Dennis Murphy
  • Patent number: 10280199
    Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: May 7, 2019
    Assignee: Phibro Animal Health Corporation
    Inventor: Byoung-Kwan Kim